Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report)'s stock price fell 3.1% during trading on Tuesday . The stock traded as low as $4.87 and last traded at $4.93. 247,739 shares were traded during trading, a decline of 91% from the average session volume of 2,847,080 shares. The stock had previously closed at $5.09.
Analyst Upgrades and Downgrades
Several analysts have issued reports on SLDB shares. Truist Financial began coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 price target for the company. HC Wainwright boosted their price objective on shares of Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a report on Monday. Wedbush initiated coverage on Solid Biosciences in a report on Friday, December 13th. They set an "outperform" rating and a $16.00 target price for the company. JPMorgan Chase & Co. cut their price target on shares of Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a report on Thursday. Finally, JMP Securities assumed coverage on Solid Biosciences in a research report on Tuesday, December 10th. They set an "outperform" rating and a $15.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Solid Biosciences currently has an average rating of "Buy" and an average price target of $15.70.
Check Out Our Latest Report on SLDB
Solid Biosciences Stock Down 2.0 %
The firm has a fifty day moving average price of $4.18 and a two-hundred day moving average price of $5.47. The stock has a market capitalization of $391.26 million, a P/E ratio of -1.66 and a beta of 1.98.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of Solid Biosciences during the fourth quarter valued at approximately $34,000. Corton Capital Inc. bought a new position in shares of Solid Biosciences during the fourth quarter valued at $41,000. Invesco Ltd. purchased a new stake in shares of Solid Biosciences during the fourth quarter valued at $49,000. Sei Investments Co. purchased a new position in Solid Biosciences in the 4th quarter worth about $52,000. Finally, Wells Fargo & Company MN lifted its stake in Solid Biosciences by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company's stock valued at $53,000 after acquiring an additional 2,986 shares during the period. Institutional investors own 81.46% of the company's stock.
About Solid Biosciences
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Further Reading
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
